Comparative Pharmacology
Head-to-head clinical analysis: BROMFED DM versus PHERAZINE VC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMFED DM versus PHERAZINE VC.
BROMFED-DM vs PHERAZINE VC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brompheniramine is a first-generation alkylamine antihistamine that competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine is a sympathomimetic amine that directly stimulates alpha-adrenergic receptors, causing vasoconstriction and decongestion. Dextromethorphan is an NMDA receptor antagonist and sigma-1 receptor agonist that acts on the medullary cough center to suppress cough.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; chlorpheniramine is a first-generation antihistamine that antagonizes histamine H1 receptors; promethazine is a phenothiazine derivative with antihistamine, sedative, antiemetic, and anticholinergic effects.
1 capsule (brompheniramine maleate 6 mg, dextromethorphan HBr 30 mg) orally every 6 hours, not to exceed 4 capsules per 24 hours.
10 mg orally every 6 hours as needed; maximum 60 mg per day.
None Documented
None Documented
Brompheniramine: 24–36 h; pseudoephedrine: 5–8 h; dextromethorphan: 2–4 h (CYP2D6 extensive metabolizers) or up to 24 h (poor metabolizers).
Terminal elimination half-life is approximately 9-16 hours; clinical context: steady-state achieved in 2-3 days.
Renal: 60–70% unchanged (brompheniramine); hepatic metabolism and renal excretion of metabolites (dextromethorphan: O-demethylation; pseudoephedrine: 70–90% unchanged in urine). Biliary/fecal: <5%.
Primarily renal as metabolites and unchanged drug; about 70% excreted in urine, 20% in feces via biliary elimination.
Category C
Category C
Cough and Cold Combination
Cough and Cold Combination